Home > Reviews > CJC-1295 Review

CJC-1295 Review 2025: Research Grade Analysis

Last Updated: February 2025 | By CellForce Labs Research Team | Contains affiliate links

What is CJC-1295?

CJC-1295 is a synthetic peptide analog of growth hormone releasing hormone (GHRH), consisting of 29 amino acids (the first 29 of the 44-amino acid GHRH molecule) with key modifications that dramatically improve its stability and half-life. The peptide exists in two primary forms: CJC-1295 with DAC (Drug Affinity Complex), which extends the half-life to approximately 8 days through albumin binding, and Modified GRF (1-29) without DAC, which has a shorter half-life of about 30 minutes but produces more physiological pulsatile GH release patterns. Both versions stimulate the anterior pituitary to release growth hormone, but their pharmacokinetic profiles differ significantly.

Category	Growth Hormone Secretagogue
Also Known As	CJC 1295, CJC-1295 DAC, Modified GRF 1-29
Research Status	Preclinical + clinical studies
Key Function	Growth hormone releasing hormone analog
Half-Life	~30 minutes (no DAC) / ~8 days (with DAC)

Research Benefits of CJC-1295

• Growth Hormone Stimulation: Potent stimulation of natural GH release from the pituitary, increasing circulating GH and IGF-1 levels.
• Improved Body Composition: Research demonstrates enhanced lean mass and reduced adipose tissue in animal models.
• Recovery Enhancement: Elevated GH levels support faster tissue repair and recovery from physical stress.
• Sleep Quality: GH secretagogues may improve deep sleep (slow-wave sleep), which is when natural GH release peaks.
• Anti-Aging Research: Age-related GH decline is a key area of longevity research, and CJC-1295 helps restore more youthful GH pulsatility.
• Synergy with Ipamorelin: When combined with the GHRP Ipamorelin, CJC-1295 produces amplified GH release through complementary receptor pathways.

Mechanism of Action

CJC-1295 works by binding to GHRH receptors on somatotroph cells in the anterior pituitary gland. This activates the cAMP signaling pathway, leading to synthesis and secretion of growth hormone. Unlike exogenous GH administration, CJC-1295 stimulates the natural pulsatile release pattern, maintaining the hypothalamic-pituitary feedback loop. The DAC version achieves prolonged action by covalently binding to serum albumin via a reactive succinimide group, dramatically extending its plasma half-life. The non-DAC version (Mod GRF 1-29) uses four amino acid substitutions (Ala2, Glu8, Ala15, Leu27) to resist enzymatic degradation while maintaining a more natural, pulsatile GH release pattern.

Research Protocols

Parameter	Research Data
Mod GRF (no DAC)	100-300 mcg, 2-3x daily
CJC-1295 DAC	1-2mg, 1-2x weekly
Administration	Subcutaneous injection
Common Stack	Combined with Ipamorelin 100-300 mcg
Research Duration	8-12 weeks typical
Best Timing	Pre-sleep or fasted state

Visit our Reconstitution Calculator for dosing calculations.

Side Effects & Safety Profile

CJC-1295 has a generally well-tolerated safety profile in research. Common observations include temporary flushing or warmth after injection, water retention (particularly with the DAC version), increased hunger, and tingling or numbness in extremities. These effects are typically dose-dependent and transient. The non-DAC version tends to produce fewer side effects due to its shorter duration of action. No significant organ toxicity has been reported in published research at standard doses.

Where to Buy CJC-1295

Vendor	Price	Testing	Rating	Link
Swiss Chems	$34.95 (2mg)	3rd-party HPLC + MS	4.8/5	Buy →
Peptide Sciences	$39.99 (2mg)	3rd-party HPLC	4.7/5	Buy →
Amino Asylum	$24.99 (2mg)	In-house	4.3/5	Buy →

Related Research

• CJC-1295 Benefits
• CJC-1295 Dosage Guide
• CJC-1295 Side Effects
• Where to Buy CJC-1295
• CJC-1295 vs Ipamorelin
• CJC-1295 vs Sermorelin
• Best Growth Hormone Peptides

Frequently Asked Questions

What is CJC-1295 used for in research?

CJC-1295 is researched as a growth hormone secretagogue that stimulates natural GH release from the pituitary gland. Research applications include body composition studies, recovery research, sleep quality analysis, and anti-aging investigations.

What is the difference between CJC-1295 with and without DAC?

CJC-1295 with DAC has a half-life of ~8 days and produces sustained GH elevation. Without DAC (Mod GRF 1-29), the half-life is ~30 minutes, producing more natural pulsatile GH release. Most researchers prefer the non-DAC version for its more physiological release pattern.

Can CJC-1295 be combined with Ipamorelin?

Yes, CJC-1295 (Mod GRF) and Ipamorelin are frequently combined in research. CJC-1295 acts on GHRH receptors while Ipamorelin acts on ghrelin receptors, producing synergistic GH release through complementary mechanisms.